KALV KalVista Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: KALV
Price (delayed)
$11.28
Market cap
$569.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.94
Enterprise value
$449.62M
Relative Growth:
Rel. Growth:
3
Relative Strength:
Rel. Strength:
32
Relative Valuation:
Rel. Valuation:
1
Relative Profitability:
Rel. Profitability:
12
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary
Highlights
KalVista Pharmaceuticals's debt has decreased by 19% YoY and by 7% QoQ
KALV's quick ratio is down by 35% year-on-year but it is up by 3.3% since the previous quarter
KALV's equity has dropped by 76% year-on-year and by 57% since the previous quarter
KalVista Pharmaceuticals's net income has decreased by 43% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of KALV
Market
Valuations
Earnings
Shares outstanding
50.52M
Market cap
$569.9M
Enterprise value
$449.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
13.81
Price to sales (P/S)
423.18
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
315.3
Revenue
$1.43M
Gross profit
$836,000
Operating income
-$202.79M
Net income
-$203.1M
EBIT
-$188.24M
EBITDA
-$186.69M
Free cash flow
-$168.47M
Per share
Balance sheet
Liquidity
EPS
-$3.94
EPS diluted
-$3.94
Free cash flow per share
-$3.15
Book value per share
$0.82
Revenue per share
$0.03
TBVPS
$4.03
Total assets
$215.51M
Total liabilities
$174.72M
Debt
$4.02M
Equity
$40.79M
Working capital
$167.52M
Debt to equity
0.1
Current ratio
5.37
Quick ratio
5.04
Net debt/EBITDA
0.64
Margins
Efficiency
Dividend
EBITDA margin
-13,091.6%
Gross margin
58.6%
Net margin
-14,242.6%
Operating margin
-14,220.9%
Return on assets
-90%
Return on equity
-195.6%
Return on invested capital
-232.1%
Return on capital employed
-106.3%
Return on sales
-13,200.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KALV stock price
How has the KalVista Pharmaceuticals stock price performed over time
Intraday
2.64%
1 week
2.83%
1 month
2.92%
1 year
-1.14%
YTD
33.18%
QTD
-7.39%
Financial performance
How have KalVista Pharmaceuticals's revenue and profit performed over time
Revenue
$1.43M
Gross profit
$836,000
Operating income
-$202.79M
Net income
-$203.1M
Gross margin
58.6%
Net margin
-14,242.6%
KalVista Pharmaceuticals's net income has decreased by 43% YoY and by 11% from the previous quarter
KALV's operating income is down by 30% YoY and by 8% QoQ
Price vs fundamentals
How does KALV's price correlate with its fundamentals
Growth
What is KalVista Pharmaceuticals's growth rate over time
Valuation
What is KalVista Pharmaceuticals stock price valuation
P/E
N/A
P/B
13.81
P/S
423.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
315.3
The EPS has contracted by 10% YoY and by 7% from the previous quarter
The P/B is 77% higher than the last 4 quarters average of 7.6
KALV's equity has dropped by 76% year-on-year and by 57% since the previous quarter
Efficiency
How efficient is KalVista Pharmaceuticals business performance
KalVista Pharmaceuticals's return on equity has shrunk by 101% YoY and by 46% QoQ
KalVista Pharmaceuticals's return on invested capital has shrunk by 99% YoY and by 39% QoQ
The ROA fell by 9% YoY and by 9% QoQ
Dividends
What is KALV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KALV.
Financial health
How did KalVista Pharmaceuticals financials performed over time
KALV's total assets is 23% higher than its total liabilities
KalVista Pharmaceuticals's current ratio has decreased by 37% YoY
KALV's quick ratio is down by 35% year-on-year but it is up by 3.3% since the previous quarter
KalVista Pharmaceuticals's debt is 90% lower than its equity
The debt to equity has soared by 100% from the previous quarter
KALV's equity has dropped by 76% year-on-year and by 57% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.